-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

632.O1.6 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Novel Therapeutic Approaches

Symposia: Chronic Myeloid Leukemia: Clinical and Epidemiological Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Clinical Research, CML, Combination therapy, Chronic Myeloid Malignancies, Diseases, Therapies, Myeloid Malignancies
Monday, December 11, 2023: 2:45 PM-4:15 PM
Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)
Moderators:
Carmen Fava, MD, PhD, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy and Ehab L. Atallah, MD, Medical College of Wisconsin
Disclosures:
No relevant conflicts of interest to declare.
2:45 PM

David T Yeung, MBBS, PhD, BSc, FRACP, FRCPA1,2,3, Naranie Shanmuganathan, MBBS, FRACP, FRCPA, PhD1,4, John Reynolds, BSc, MSc, PhD5*, Susan Branford, PhD6, Mannu Walia, PhD7*, Agnes S. M. Yong, MD, PhD8, Jake Shortt9, Kate Burbury, MD10*, Lynette C.Y. Chee, MBBS, PhD, FRACP, FRCPA11, Nick Viiala, MBBS FRCPA FRACP12, Ilona Cunningham, MBBS FRACP FRCPA13, David M. Ross, MBBS, PhD, FRACP, FRCPA14*, Alwyn Bernard D'Souza, MBBS, FRACP, FRCPA15*, Matthew P.F. Wright, MBBS, FRCPA, FRACP16*, Rosemary Anne Harrup17*, Cecily Forsyth, FRACP, FRCPA, MBBS18, Robin Filshie, PhD, FRACP, FRCPA19, Peter J. Browett20, Steven W. Lane, MD, PhD21, Carolyn Grove22, Andrew P Grigg, MBBS, MD, FRACP, FRCPA23*, Timothy P Hughes, MD, MBBS, FRACP, FRCPA24 and on Behalf Of The ALLG25*

1Blood Cancer, Precision Medicine Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia
2Haematology, Central Adelaide Local Health Network (CALHN), Adelaide, SA, Australia
3Australasian Leukaemia and Lymphoma Group (ALLG), Melbourne, Australia
4Haematology, Central Adelaide Local Health Network (CALHN), Adelaide, Australia
5Australian Centre for Blood Diseases, Monash University, Melbourne, Australia
6Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA, Australia
7Australasian Leukaemia and Lymphoma Group, Melbourne, Australia
8Haematology Department, Royal Perth Hospital, Perth, Australia
9Monash University and Monash Health, Melbourne, VIC, Australia
10Peter MacCallum Cancer Centre, East Melbourne, AUS
11Department of Clinical Haematology and Bone Marrow Transplant Service, The Royal Melbourne Hospital, Parkville, Australia
12Liverpool Hospital, Sydney, AUS
13Haematology Department Concord Hospital, Concord and University of Sydney, Sydney, Australia
14Department of Haematology, Flinders Medical Centre and University, Adelaide, SA, Australia
15Wellington Hospital, Wellington, New Zealand
16Fiona Stanley Hospital, Murdoch, WEA, AUS
17Royal Hobart Hospital, University of Tasmania, Tasmania, Australia
18Wyong Hospital, North Gosford, AUS
19St. Vincent's Hospital Melbourne, Fitzroy, VIC, AUS
20University of Auckland School of Medicine, Auckland, NZL
21Cancer Program, QIMR BERGHOFER MEDICAL RESEARCH, Herston, Brisbane, AUS
22Department of Haematology, Sir Charles Gairdner Hospital and PathWest, Perth, AUS
23Austin Hospital, Melbourne, VIC, AUS
24South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia
25ALLG, Melbourne, Australia

3:00 PM

Timothy P Hughes, MD, MBBS, FRACP, FRCPA1, Giuseppe Saglio, MD2, Jan Geissler3*, Dong-Wook Kim, MD, PhD4, Elza Lomaia, MD, PhD5*, Jiri Mayer, MD6, Anna Turkina, MD7*, Shruti Kapoor, MS8*, Ana Paula Torres Cardoso, MD, PhD9*, Jomy Jose10*, Monali Sura, MS9* and Jorge Cortes, MD11

1South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia
2Dept. of Clinical and Biological Sciences, University of Turin, Turin, Italy
3CML Advocates Network, Bern, Switzerland
4Uijeongbu Eulji Medical Center, Uijeoungbu-si, Korea, Republic of (South)
5Almazov National Medical Research Centre, St. Petersburg, Russian Federation
6Department of Internal Medicine-Hematology and Oncology, Masaryk University and University Hospital, Brno, Czech Republic
7National Medical Research Center for Hematology, Moscow, Russian Federation
8Novartis Pharmaceuticals Corporation, East Hanover, NJ
9Novartis Pharmaceuticals Corporation, East Hanover
10Novartis Pharma AG, Basel, Switzerland
11Georgia Cancer Center, Augusta University, Augusta, GA

3:15 PM

Qian Jiang, MD1, Yanli Zhang, MD2*, Qiang Wang, MD3*, Jianyu Weng, MD4*, Zhenfang Liu, MD5*, Suning Chen, MD6*, Li Weiming, MD7*, Bingcheng Liu, MD8*, Zhuogang Liu, MD9*, Yihan Wang, PhD10* and Jingrong Cao, PhD10*

1Peking University Peoples Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, Beijing, China
2Department of Hematology, Henan Cancer Hospital, Zhengzhou, China
3Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
4Guangdong Provincial People's Hospital, Guangzhou, China
5Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
6National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
7Department of Hematology, Union Hospital, Tongji Medical Collage, Huazhong University of Science and Technology, Wuhan, China
8State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, China
9Shengjing Hospital of China Medical University, Shenyang, China
10Shenzhen TargetRx, Inc., Shenzhen, China

3:30 PM

Jorge Cortes, MD1, Fabian Lang, MD2*, Delphine Rea, MD, PhD3, Andreas Hochhaus, MD4, Massimo Breccia5*, Yeow Tee Goh, MBBS6, Michael C. Heinrich, MD7*, Timothy P Hughes, MD, MBBS, FRACP, FRCPA8, Jeroen J.W.M. Janssen, MD, PhD9, Philipp le Coutre, MD10*, Hironobu Minami, MD11*, Koji Sasaki, MD12, Daniel J. DeAngelo, MD13, Gessami Sanchez-Olle14*, Nathalie Pognan15*, Jomy Jose14*, Matthias Hoch14* and Michael Mauro, MD16

1Georgia Cancer Center, Augusta University, Augusta, GA
2Hematology/Oncology, Klinikum der Goethe Universität, Frankfurt/Main, Germany
3Hematology Department, Hôpital Saint-Louis, Paris, France
4Universitätsklinikum Jena, Jena, Germany
5Department of Translational and Precision Medicine, Hematology-Sapienza University, Rome, Italy
6Department of Hematology, Singapore General Hospital, Singapore, Singapore
7Department of Medicine, Division of Hematology and Oncology, Portland VA Health Care System and Oregon Health & Science University, Knight Cancer Institute, Portland, OR
8South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia
9Department of Hematology, Amsterdam University Medical Centers, VUmc, Amsterdam, Netherlands
10Charité-Universitätsmedizin Berlin, Berlin, Germany
11Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe, Japan
12Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
13Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
14Novartis Pharma AG, Basel, Switzerland
15Global Drug Development, Novartis Pharma SAS, Rueil-Malmaison, France
16Memorial Sloan Kettering Cancer Center, New York, NY

3:45 PM

Qian Jiang, MD1, Zongru Li2*, Gongli Zhang3*, Yu Hu, MD4*, Weiming Li5*, Yongping Song, MD6*, Junmin Li7*, Li Zhou7*, Bingcheng Liu, MD8*, Xiaoli Liu9*, Na Xu9*, Suning Chen, MD10*, Zhenfang Liu11*, Huanling Zhu12*, Jie Jin13, He Huang13*, Sixuan Qian14*, Li Meng15*, Xin Du, MD16*, Xielan Zhao17*, Sujun Gao18*, Yang Liang, MD, PhD19, Ming Hou20*, Wei Wang21*, Zi Chen22*, Qian Niu22*, Lichuang Men22*, Dajun Yang23,24*, Yifan Zhai23,24 and Xiaojun Huang2*

1Peking University Peoples Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, Beijing, China
2Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
3Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
4Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
5Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
6Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
7Ruijin Hospital, Shanghai Jiaotong University School Of Medicine, Shanghai, China
8Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
9Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
10National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China
11The First Affiliated Hospital of Guangxi Medical University, Nanning, China
12Department of Hematology, West China Hospital of Sichuan University, Chengdu, China
13The First Affiliated Hospital, College of Medicine, Zhejiang University, Hematology, Hangzhou, China
14Jiangsu Province Hospital, Jiangsu, China
15Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
16Division of Hematology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
17Xiangya Hospital Central South University, Changsha, China
18The First Hospital of Jilin University, Changchun, China
19Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
20Qilu Hospital of Shandong University, Shandong, China
21The Affiliated Hospital of Qingdao University, Qingdao, China
22Guangzhou Healthquest Pharma Co. Ltd., Guangzhou, China
23Guangzhou Healthquest Pharma Co., Ltd., Guangzhou, China
24Ascentage Pharma Group Inc., Rockville, MD

4:00 PM

Fadi G. Haddad, MD1*, Elias Jabbour2, Koji Sasaki, MD1, Lewis Nasr1*, Xuelin Huang, PhD3*, Ghayas C. Issa4, Farhad Ravandi, MD, MBBS5, Guillermo Garcia-Manero, MD6, Tapan M. Kadia, MD1, Naval Daver, MD1, Yesid Alvarado Valero, MD1, Cedric Nasnas1*, Maro Ohanian, DO1*, Nicholas J. Short, MD1, Lucia Masarova, MD1, Marianne Zoghbi1*, Patrice Eric Nasnas, MD7*, Guillermo Montalban-Bravo, MD1, Jeffrey Skinner7*, Sherry Pierce, BSN, BA1*, Michael Andreeff, MD PhD1 and Hagop M. Kantarjian, MD1

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2University of Texas M.D. Anderson Cancer Ctr., Houston, TX
3Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
4The University of Texas MD Anderson Cancer Center, Houston, TX
5MD Anderson Cancer Center, Houston, TX
6University of Texas MD Anderson Cancer Center, Houston, TX
7Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

*signifies non-member of ASH